SubHero Banner

Norditropin® FlexPro (somatropin) – New indications and updated warnings

February 23, 2018 - The FDA approved Novo Nordisk’s Norditropin FlexPro (somatropin), for the treatment of idiopathic short stature (ISS), height standard deviation score (HSDS) < -2.25, and associated with growth rates unlikely to permit attainment of adult height in the normal range, and growth failure due to Prader-Willi syndrome (PWS).

Download PDF